MIRA PHARMACEUTICALS, INC. — Form 8-K
Filed July 31, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 92/100
What the filing says
On July 27, 2026, Mira Pharmaceuticals received notice of failure to satisfy continued listing requirements or standards, triggering a delisting review. The filing does not specify which exchange, which listing rule was violated, or what remedial actions are available. For a $16M market-cap company, delisting represents an existential threat to liquidity and market access.
Why this rating
Delisting jeopardizes equity trading, investor access, and survival; existential risk at this company scale. Near-total loss of market value likely.
Extracted items
See more from July 31, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.